FDA agrees to use liver medications to treat Alzheimer's disease

The US Food and Drug Administration today approved an innovative drug designed to treat liver infections as an unexpected treatment for people with Alzheimer's disease..

Scientists have discovered that the drug, which contains the active ingredient Lonavarnib, prevents brain damage and improves behavioral symptoms in mice..

The drug was originally prescribed by the Food and Drug Administration for the treatment of hepatitis D , Hepatitis virus that runs through body fluids.

In the new study, genetic engineering researchers discovered during a research on mice that the drug "Lonavarnib" prevented the formation of the protein "Tao", a protein believed to cause Alzheimer's disease..

"Although tau-related diseases, including Alzheimer's disease and chronic encephalopathy, constitute serious public health problems, there is currently no cure available," said Dr. Isarel Hernandez of the University of California,.

Upstream interventions have shown some efficacy in animal models, but none of these methods have been successful in human clinical trials to date.

This study suggests that treatment using lonafarnib Can be effective only in the early stages of the disease, thus reinforcing the importance of research in the early detection of diseases such as Alzheimer's disease.